glp-1 drug coverage Employers Grapple with Claims Costs versus Outcomes of Drugs Designing fiscally viable coverage of

Neuropsychopharmacology 45 (3), 451461

Common reported side effects include nausea, vomiting, constipation, diarrhea, reduced appetite, and unusual skin sensations

4,35 The immediate-release (IR) formulation of exenatide (Byetta , Amylin Pharmaceuticals, San Diego, CA, USA) was first developed in 2005 to treat type 2 diabetes (Table 1)

39 It was approved by the US FDA in 2014 to treat obesity (Saxenda , Novo Nordisk, Plainsboro, NJ, USA), after first being approved as a type 2 diabetes medication (Victoza , Novo Nordisk) in 2010 (Table 1)

50 Research has shown that GLP-1 and its related compounds significantly affect these processes in rat fat cells

The underlying mechanisms of cardiovascular and renal protection differ partially between GLP1-RAs (mainly anti-atherogenic and vascular effects) and SGLT2is (primarily systemic and intrarenal hemodynamic changes)